METAPRO: Metagenomics and genomic approaches for the prevention of the spread of plazomicin resistance in humans, animals and the environment
Conference in One Health EJP Annual Scientific Meeting
April 11st, 2022
Rodriguez-Matamoros B.
Plazomicin is a novel semisynthetic aminoglycoside approved in June 2018 by the FDA to be used as a last resort antibiotic in complicated urinary tract infections (UTI) caused by multidrug resistant Gram-negative bacteria in humans. Approval by the EMEA is foreseen in 2019. However, the expression of acquired 16S rRNA methyltransferases by bacteria results in complete resistance to plazomicin. Added to the high level of resistance to this novel compound, bacteria harbouring these determinants show resistance to all clinically relevant aminoglycosides. We identified in 2005 worldwide the first bacterium from animal origin bearing one such 16S rRNA methyltransferase. Since, us and other researchers have identified 13 of such methyltransferases, and they have been found in human, animal, food and environmental sources. Recent studies show that, despite not being as prevalent as other resistance mechanisms, these methyltransferases are already globally present, jeopardizing the use of this critically needed antibiotic
|
|
|
|
 | Centro de Vigilancia Sanitaria Veterinaria (VISAVET). Universidad Complutense (UCM). |
| Departamento de Sanidad Animal. Facultad de Veterinaria. Universidad Complutense (UCM). |
Link to One Health EJP Annual Scientific Meeting
